# Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)

> **NCT04619342** · NA · UNKNOWN · sponsor: **Beijing Tsinghua Chang Gung Hospital** · enrollment: 98 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)

## Interventions

- **DEVICE:** GSMs-TACE
- **PROCEDURE:** Surgical Resection

## Key facts

- **NCT ID:** NCT04619342
- **Lead sponsor:** Beijing Tsinghua Chang Gung Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-30
- **Primary completion:** 2021-06-30
- **Final completion:** 2022-12-31
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2020-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04619342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04619342, "Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04619342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*